EUVIMED · CrossrefJournal
Cancer Biotherapy and Radiopharmaceuticals
ISSN 1084-9785 · SAGE Publications
Latest articles
Beyond Prostate-Specific Membrane Antigen: The Design and Future of Novel Radiopharmaceuticals Targeting the Tumor Microenvironment
Engrailed-1 Promotes Tumor Progression and Metastasis in Papillary Thyroid Cancer
Prediction of the Efficacy of PA-TACE in Patients with Clearly Defined Hepatocellular Carcinoma by Imaging Combined with Serology: A Retrospective Cohort Study with a Two-Center Follow-Up of up to 12 Years
Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma
Ultrasound-Responsive Folate-Chlorogenic Acid Nanocarrier Targeting Mixed Lineage Kinase 1 for Enhanced Wilms Tumor Therapy
Impact of Nurse-Coordinated Care on Outcomes of Ultrasound-Assisted Radiopharmaceutical Cancer Therapy
Prospective Clinical Assessment of Ultrasound-Assisted Radiopharmaceutical Imaging Under Anesthesia for Oncologic Evaluation
Ultrasound-Enhanced CRISPR–Curcumin Nanoparticles for Gene-Modulating Therapy in Metastatic Pulmonary Lesions
Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection
Development of a 177 Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection
Synergistic Mechanisms and Clinical Progress of Radionuclide Therapy Combined with Immune Checkpoint Inhibitors in Colorectal Cancer
Clinical Laboratory Evaluation of the Biodistribution of a Radiolabeled Antimicrobial Peptide for Precision Radiopharmaceutical-Guided Radionuclide Therapy in Severe Pneumonia Among Immunocompromised Patients with Cancer
Single-Cell Transcriptomics in Triple-Negative Breast Cancer: Implications for Radionuclide Therapy in Precision Oncology
Curved Vertebroplasty System Combined with Targeted Radionuclide Therapy for Tumor-Related Pathological Vertebral Fractures
Radionuclide-Based Theranostic Mapping for Spatially Optimized Treatment Planning in Cervical Carcinoma
MICA/MICB-Mediated NKG2D Immune Escape in Cervical Cancer: Single-Cell Transcriptomic Mapping of Radionuclide Therapy Targets for Precision Radioimmunotherapy
Radionuclide Therapy Integrated Multimodal Transsylvian Microneurosurgical Management of Type 5 Insular and Paralimbic Gliomas for Precision Oncology
Effects of Perioperative 177 Lutetium-Labeled Targeted Radionuclide Therapy on Inflammatory Response and Intestinal Recovery in Colorectal Cancer
Precision Locoregional Therapy Combined with Immune Checkpoint Blockade for Intermediate-Advanced Hepatocellular Carcinoma
Precision Oncology with 177 Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer
Radiopharmaceutical-Guided Personalized Adjuvant Radiotherapy Planning after Esophageal Cancer Resection
CavitoMod-UTMDNet: A Mechanistic Cavitation–Diffusion Framework for Ultrasound-Targeted Microbubble Destruction–Enhanced Liposomal Doxorubicin Delivery in Pancreatic Cancer
Ultrasound-Assisted Radiopharmaceutical Investigation of GNL1-Mediated AKT-P53-P21 Axis Activation in Cervical Cancer Progression
Ultrasound-Potentiated Targeting of GLS1 by an Oridonin Derivative (R13) in Multiple Myeloma: Therapeutic Efficacy and Safety Considerations
18 F-FDG PET/CT Combined with Serum Tg and BRAF V600E Mutation for Evaluating Recurrence/Metastasis in RAIR-DTC: Subgroup Analysis and Clinical Decision-Making Value
Advancing β-Glucan-Based Immunomodulation and Nanotherapeutic Strategies for Cancer Biotherapy
Acknowledgment of Reviewers 2025
Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)
Ultrasound-Mediated Microbubble Disruption to Enhance Radiopharmaceutical Access to the Tumor Microenvironment in Immune-Resistant Lung Carcinoma
EUVIMED